Analysis of peptide regulation, FDA compounding decisions, and shifts in the vendor and supplier market, with sources cited in every post. For daily price movements and stock changes, see Price Changes.
Health Canada found bacteria in injectable peptides from Shanghai ERP Peptide and seized over 11,400 vials from the company and two online retailers.
Chameleon Peptides has replaced its store with a closure notice. What the notice says, what it sold, and five vendors stocking the same compounds.
Compare the KLOW and GLOW peptide blends: what each vial holds, what KPV adds, each component's FDA and HHS compounding status, and price per vial.
Compare Melanotan I and Melanotan II: structure, receptor targets, the clinical record, FDA approval and compounding status, and price per milligram.
Four vendors' storewide sales drove October 2026's price cuts, while 22 of 39 vendors changed no price. Median: $4.09 per milligram.
Compare Semax and Selank: structure, laboratory findings, the Russian clinical record, FDA and HHS compounding status, and price per milligram.
HHS will not act against pharmacies compounding BPC-157, TB-500, MOTS-c, KPV, Semax or Epitalon if ten conditions are met. What the policy says.
Compare tesamorelin, sermorelin and ipamorelin: receptor targets, clinical trial findings, FDA approval history and price per milligram.
GLP-3 is not a hormone or a drug class. It is a vendor code for retatrutide. How GLP-1, GLP-2 and GLP-3 product codes work, and what retatrutide costs.
Eli Lilly sued 11 businesses it says sell retatrutide, six in August and five in October 2026. Three cases are dismissed and two defendants have moved to dismiss.
An FDA interim access policy for compounding certain peptides is under White House review. What the filing shows, what is reported, and what is still open.
As of October 2026, peptide blends cost less than the same compounds sold as separate vials at the same vendor, and the gap grows with each compound added.
How peptides degrade, what heat, moisture, light and freezing do to them, and how to store bacteriostatic water and reconstituted peptides.
FDA concluded again on October 2, 2026 that retatrutide is not a biological product. Days later the government told the Seventh Circuit it lacks jurisdiction.
Soma Chems has stopped taking orders and replaced its store with a short notice. What it sold, and five vendors stocking the same compounds.
WADA's 2027 list names BPC-157, TB-500, MOTS-c, ipamorelin and now SLU-PP-332. Semaglutide and tirzepatide remain monitored, not prohibited.
Tirzepatide, retatrutide and semaglutide listings were cut three times as often as the rest of the index in September 2026. Median: $4.80 per milligram.
The Seventh Circuit heard Eli Lilly's appeal over whether retatrutide is a protein on September 24, 2026, then asked whether it can hear the case at all.
What each part of a peptide certificate of analysis measures (identity, purity, content and endotoxin) and what the report cannot show about a vial.
Eternal Peptides has replaced its store with a farewell notice, and support ends September 30, 2026. What it sold, and five vendors stocking the same compounds.
WIRED and a separate investigation tested eight INDR Labs vials bought at two Brooklyn stores. None produced a confirmed match to the ingredient on its label.
Compare retatrutide, tirzepatide and semaglutide: receptor targets, head-to-head and placebo-controlled trial findings, side effects and FDA approval status.
The vendor that raised prices 10% in July cut them by a median of 21% in August 2026, more than undoing the increase. Median listed price: $4.90 per milligram.
On July 28, 2026 FDA revised 17 draft guidances for generic peptide drugs and withdrew its 2021 synthetic-peptide guidance. Comments close September 28.
Listed prices on the peptides an FDA panel recommended in July 2026 changed no more than the rest of the market, and no more than the one it rejected.
A general exclusion order has covered tirzepatide imports since April 2025. It binds every importer, not only the companies Eli Lilly named. Here is its scope.
The largest vendor in the index raised prices about 10% across its catalog in July 2026 while three others cut. Median listed price: $4.90 per milligram.
Strate Labs has closed and its site comes down permanently on August 1, 2026. What the federal record shows, and five vendors stocking the same compounds.
FDA will weigh cathelicidin LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF before March 2027. Two are stocked by nearly every vendor we index, and one by two.
Slate Research stopped resolving on June 22, 2026. What we can confirm, what we cannot, and five vendors still stocking the compounds it sold.
Four vendors drove nearly all of June 2026's price decline while ten changed nothing at all, leaving the index almost flat. Median: $4.92 per milligram.
The median research peptide's highest-priced listing cost about three times its lowest-priced listing in May 2026. Median listed price: $4.90 per milligram.
An FDA panel voted to recommend adding BPC-157, KPV, TB-500 and three more peptides to the 503A compounding list. What the vote does and does not change.
